Dr. Jou, Yuh-Shan
Distinguished Research Fellow
- 27899062,26523525(Lab) (Lab) (Room No: N606)
- 26523521(O)
- 27827654 (Fax)
-
Specialty:
- Cancer Genomics
- Molecular Cancer Biology
- Bioinformatics
Education and Positions:
Ph.D., Michigan State University
Highlight Detail
HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy.
Dr. Jou, Yuh-Shan
Clin Cancer Res., Jul 18, 2012Histone deacetylase inhibitors (HDACi) are actively explored as new-generation epigenetic drugs but have low efficacy in cancer monotherapy. To reveal new mechanism for combination therapy, we show that HDACi induce cell death but simultaneously activate tumor-progressive genes to ruin therapeutic efficacy.